Multidisciplinary coordination meetings : a new approach
Multidisciplinary Coordination Meetings (RCP, "Réunion de Concertation Pluridisciplinaire) were organised in the framework of the first French national cancer plan (2003 – 2007). Today, those meetings are an essential step in the organisation of cancer care. Recent developments in the techniques used for molecular screening and the evaluation of their use in numerous clinical trials have led to a new type of multidisciplinary coordination meeting being created.
Institut Curie has set up a Molecular Biology Board in October 2014 by reproducing the organisation established during the SHIVA clinical trial. The molecular RCP is coordinated by Dr Christophe Le Tourneau (IC) for adult and paediatric patients.
All patients suffering from a metastatic cancer, relapse or suffering from a rare cancer can register for the molecular RCP via their appointed medical oncologist. This meeting aims at determining whether it is appropriate to research molecular alterations in a patient that could be targeted by treatment. When this is the case the team determine the sampling and the quality control to be carried out by pathologists. The molecular analyses are performed and the biologists from the pharmocogenetic and somatic genetic units at Institut Curie interpret the results. They determine whether the tumour is presenting an alteration for which treatment is available as part of a clinical trial.
Valuable time gained for patients
The inclusion of molecular characterisation when setting up the RCP means that patients can be precisely and rapidly orientated towards the best-adapted clinical trial for them. This new organisation, which is scientifically managed by Maud Kamal (IC), reduces the time wasting that would be associated with iterative research for a type of molecular anomaly that is specific to one clinical trial.
An original and innovative organisation
Today the delivery period for genomic analysis results is less than 4 weeks.
Expertise gathered for the process
By inviting geneticists to the routine multidisciplinary coordination meetings, the board benefits from the multidisciplinary expertise of the Institut in order to optimise the treatment decision.
These weekly meetings unite numerous experts with complementary skills: